$7.26+0.41 (+5.99%)
Profound Medical Corp.
Profound Medical Corp. in the Healthcare sector is trading at $7.26 with a market capitalization of $242M. Wall Street consensus targets $11.14 (5 analysts), implying a +53.4% move over the next 12 months. The stock is currently 19% below its 52-week high of $8.95, remaining 7.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.34M↓ | $5.98M↑ | $5.29M↑ | $2.21M↓ | $2.62M |
| Gross Profit | $3.83M↓ | $3.99M↑ | $3.93M↑ | $1.62M↓ | $1.85M |
| Operating Income | -$8.02M↓ | -$7.37M↑ | -$8.91M↑ | -$13.81M↓ | -$11.17M |
| Net Income | -$7.05M↑ | -$8.18M↓ | -$7.98M↑ | -$15.70M↓ | -$10.72M |
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO sy...
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outperforming the Russell 2000 Growth Index’s –2.80%, HFRI Equity Hedge Index’s -0.24%, and the HFRI Fundamental […]
The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supported by new clinical data, payer progress and a growing installed base. For the three months ende